share_log

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Cuts Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Defense World ·  Jan 21, 2023 07:01

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. trimmed its position in AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating) by 2.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,528 shares of the medical instruments supplier's stock after selling 1,935 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. owned 0.20% of AngioDynamics worth $1,627,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Texas Permanent School Fund raised its holdings in shares of AngioDynamics by 2.1% during the 2nd quarter. Texas Permanent School Fund now owns 28,029 shares of the medical instruments supplier's stock valued at $542,000 after buying an additional 580 shares during the period. US Bancorp DE raised its holdings in shares of AngioDynamics by 36.2% during the 2nd quarter. US Bancorp DE now owns 2,562 shares of the medical instruments supplier's stock valued at $50,000 after buying an additional 681 shares during the period. Legal & General Group Plc raised its holdings in shares of AngioDynamics by 0.9% during the 2nd quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier's stock valued at $1,802,000 after buying an additional 851 shares during the period. Brinker Capital Investments LLC raised its holdings in shares of AngioDynamics by 2.3% during the 1st quarter. Brinker Capital Investments LLC now owns 41,539 shares of the medical instruments supplier's stock valued at $895,000 after buying an additional 929 shares during the period. Finally, Mutual of America Capital Management LLC raised its holdings in shares of AngioDynamics by 16.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 6,513 shares of the medical instruments supplier's stock valued at $126,000 after buying an additional 934 shares during the period. 94.94% of the stock is currently owned by hedge funds and other institutional investors.

Get AngioDynamics alerts:

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ANGO shares. Raymond James dropped their target price on AngioDynamics from $25.00 to $22.00 and set a "strong-buy" rating on the stock in a report on Friday, January 6th. StockNews.com began coverage on AngioDynamics in a report on Wednesday, October 12th. They set a "hold" rating on the stock.

AngioDynamics Price Performance

ANGO stock opened at $13.32 on Friday. The company has a quick ratio of 1.30, a current ratio of 2.16 and a debt-to-equity ratio of 0.12. AngioDynamics, Inc. has a 52-week low of $11.71 and a 52-week high of $24.87. The stock's 50 day moving average is $13.34 and its two-hundred day moving average is $17.49. The company has a market capitalization of $521.26 million, a PE ratio of -16.05 and a beta of 0.66.

AngioDynamics Profile

(Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Articles

  • Get a free copy of the StockNews.com research report on AngioDynamics (ANGO)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO – Get Rating).

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment